SUISO JAPAN and Fukuoka Dental College Launch Joint Research on Hydrogen Gas-Based Periodontal Tissue Regeneration Therapy

SUISO JAPAN Co., Ltd., a specialized manufacturer of hydrogen equipment headquartered in Takatsuki, Osaka, and operating under the Suilive brand, has decided to begin joint research with Fukuoka Dental College, operated by Fukuoka Gakuen, on periodontal tissue regeneration therapy using hydrogen gas. The study aims to shift dental treatment from extracting teeth to regenerating and preserving them, representing an initiative that could bring a new paradigm shift to dental care. In Japan, around 80% of adults are said to suffer from periodontal disease, which is the leading cause of tooth loss. However, current periodontal treatments still face several challenges, including long recovery times, variability in regenerative outcomes, and difficulty preserving teeth in severe cases. The research team is therefore focusing on hydrogen gas, a substance that has been rapidly studied in the medical field in recent years. Hydrogen combines high diffusibility, strong safety characteristics, and antioxidant and anti-inflammatory effects, and is expected to be applied in regenerative medicine as well as neurological and cardiovascular fields. This joint study is a full-scale attempt to apply these properties to dentistry. The research has three main points. First, it seeks to fundamentally optimize the healing process of periodontal tissue by using hydrogen gas to suppress inflammation and reduce oxidative stress. Second, it aims to improve regeneration speed and success rates by combining hydrogen gas with existing regenerative therapies such as FGF-2 (Regroth®). Third, it seeks to expand the possibility of preserving teeth even in severe periodontal disease, creating new options to avoid tooth extraction. Professor Yasunori Yoshinaga of the Department of Periodontology, Section of Oral Medicine and Therapy at Fukuoka Dental College, said the team will develop an innovative periodontal tissue regeneration therapy using hydrogen gas through industry-academia collaboration. Hydrogen gas is attracting attention as a next-generation medical substance because of its high diffusibility and safety. The study will verify its effectiveness in wound healing of periodontal tissue, which has a complex structure. By combining hydrogen gas with FGF-2 (Regroth®) regenerative therapy, the team aims to achieve early postoperative healing and more reliable tissue regeneration, helping protect as many teeth as possible and contributing to longer healthy life expectancy. SUISO JAPAN stated that it was the first hydrogen inhaler manufacturer in Japan to obtain ISO 13485 certification and develops products under a medical device quality management system. Using that technology, the company has developed a dedicated device that directly dissolves hydrogen gas into biological liquid, enabling faster research while maintaining high hydrogen concentrations. The company said it will continue building scientific evidence in each area of dentistry and contribute to establishing hydrogen medicine. SUISO JAPAN is promoting next-generation solutions across healthcare, wellness, and prevention, centered on hydrogen technology. This joint research marks an important step into the unexplored field of dentistry, regenerative medicine, and hydrogen. If the research progresses toward practical use, it is expected to help change the conventional idea that periodontal disease leads to tooth extraction, contribute to longer healthy life expectancy in an aging society, reduce medical costs, and improve patients’ quality of life. The study will proceed in stages, starting with the acquisition of basic data, followed by establishing efficacy and safety, and then expanding toward clinical application. In the future, the team aims for practical use in dental clinics and to contribute to standardizing regenerative dental care.